Trial Profile

Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HLD-0915 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Sponsors Halda Therapeutics

Most Recent Events

24 Feb 2025 According to a Halda Therapeutics media release, the first patient has been dosed in this trial. The Phase 1/2 clinical study could enroll up to 80 mCRPC patients.
07 Feb 2025 New trial record
04 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com